Earnings summaries and quarterly performance for GALECTIN THERAPEUTICS.
Executive leadership at GALECTIN THERAPEUTICS.
Board of directors at GALECTIN THERAPEUTICS.
BS
Benjamin S. Carson
Detailed
Director
EJ
Elissa J. Schwartz
Detailed
Director
GF
Gilbert F. Amelio
Detailed
Director
GS
Gilbert S. Omenn
Detailed
Director
HH
Harold H. Shlevin
Detailed
Director
KE
Kary Eldred
Detailed
Director
KD
Kevin D. Freeman
Detailed
Director
MR
Marc Rubin
Detailed
Director
RA
Richard A. Zordani
Detailed
Director
RE
Richard E. Uihlein
Detailed
Chairman of the Board
Research analysts who have asked questions during GALECTIN THERAPEUTICS earnings calls.
David White
David White Financials
1 question for GALT
EA
Ed Arce
WestPark Capital
1 question for GALT
Also covers: ABUS, AKBA, ARCT +5 more
LL
Len Levi
Dotdot Partners
1 question for GALT
SY
Sa'ar Yaniv
Roth Capital
1 question for GALT
TY
Thomas Yip
H.C. Wainwright & Co.
1 question for GALT
Also covers: ABUS, ARDX, ENTA +6 more
VB
Vernon Bernardino
H.C. Wainwright & Co.
1 question for GALT
Also covers: CANF, ELDN, GOVX +6 more
Recent press releases and 8-K filings for GALT.
Galectin Therapeutics receives FDA feedback and secures additional $10 million financing
GALT
Debt Issuance
New Projects/Investments
Guidance Update
- Galectin Therapeutics received FDA written feedback on its Type C meeting request for the belapectin development program, indicating alignment on the patient population proposed for enrollment in a registration trial.
- The company will pursue a follow-up Type C meeting with the FDA to finalize remaining components of the next clinical trial design and present recently generated biomarker data.
- Galectin Therapeutics entered into a new $10 million unsecured, convertible line of credit financing agreement provided by its chairman, Richard E. Uihlein.
- This additional financing, combined with existing cash resources, is expected to fund the company's currently anticipated expenditures through at least March 2027.
Dec 19, 2025, 1:00 PM
Galectin Therapeutics Provides Regulatory Update and Secures Additional $10 Million Line of Credit
GALT
New Projects/Investments
Debt Issuance
Guidance Update
- Galectin Therapeutics Inc. received a written response from the FDA regarding its belapectin development program, indicating alignment on the patient population for a registration trial and planning a follow-up meeting to finalize clinical trial design and present new biomarker data.
- On December 19, 2025, the company secured a new $10 million unsecured, convertible line of credit from Richard E. Uihlein to finance working capital needs, available through January 31, 2027.
- This new line of credit bears interest at the Applicable Federal Rate (currently 3.60%) plus 2%, with principal and interest due by June 30, 2027.
- In connection with this agreement, the company will issue warrants to purchase up to 200,000 shares of common stock, with exercise prices at 150% of the closing price on the draw date (not exceeding $10.00 per share), expiring on December 31, 2029.
- Additionally, the maturity dates for all existing convertible lines of credit and notes payable to Richard E. Uihlein have been extended to June 30, 2027, and the company anticipates its financial resources will cover expected expenditures through at least March 2027.
Dec 19, 2025, 12:55 PM
Galectin Therapeutics Reports Positive NAVIGATE Trial Biomarker Data and FDA Submission
GALT
New Projects/Investments
Product Launch
- Galectin Therapeutics Inc. presented positive biomarker and clinical findings from its NAVIGATE trial for belapectin, demonstrating a lower rate of new varices in the completer population and reduced liver stiffness.
- The company emphasized the consistency between clinical outcomes and biomarker results (including FibroScan, ELF score, PRO-C3, and YKL-40), strengthening confidence in belapectin's potential to slow disease progression in compensated MASH cirrhosis and portal hypertension.
- Galectin Therapeutics has submitted its FDA package for belapectin and is anticipating feedback soon, while also actively exploring strategic opportunities and partner discussions for the program.
- The Chairman, Richard Uihlein, extended the company's cash runway, contributing to what management considers the best year in the company's history, and belapectin showed a favorable safety profile with no drug-related serious adverse events.
Dec 3, 2025, 5:00 PM
Galectin Therapeutics Holds 2025 Annual Meeting and Provides Belapectin Clinical Update
GALT
Proxy Vote Outcomes
New Projects/Investments
Executive Compensation
- At its 2025 Annual Meeting, Galectin Therapeutics' stockholders re-elected 11 directors, ratified Cherry Bekaert LLP as the independent registered public accounting firm for FY 2025, approved executive compensation, and set the frequency for future advisory votes on executive compensation to every three years.
- CEO Joel Lewis stated that 2025 was the "best year in the company's history", with the company trading at multi-year highs, and acknowledged Chairman Richard E. Uihlein for extending the cash runway.
- CMO Khurram Jamil reported that the 2-milligram dose of belapectin demonstrated a lower rate of new varices compared with placebo after 18 months in the per protocol population of the Navigate trial.
- Further analysis in 2025 showed belapectin reduced fibrosis progression on FibroScan, positively impacted the FDA-approved ELF test, and showed favorable changes in mechanistic biomarkers and portal hypertension risk categories, all while maintaining a clean safety profile.
- Galectin Therapeutics has submitted its FDA package for belapectin and is anticipating feedback, while also exploring strategic opportunities and engaging in discussions with potential partners.
Dec 3, 2025, 4:00 PM
Galectin Therapeutics Holds 2025 Annual Meeting and Provides Corporate Update
GALT
Proxy Vote Outcomes
New Projects/Investments
Executive Compensation
- At its 2025 Annual Meeting, Galectin Therapeutics' stockholders re-elected all 11 nominated directors, approved the non-binding advisory resolution on executive compensation, and ratified Cherry Bekaert LLP as the independent auditor for fiscal year 2025.
- The company provided an update on the Belapectin Navigate trial, stating that the 2-milligram dose showed a lower rate of new varices compared to placebo in the completer population, supported by biomarker data indicating reduced fibrosis progression and positive effects on portal hypertension.
- Galectin Therapeutics has submitted its FDA package for Belapectin and is anticipating feedback soon, while also actively exploring strategic opportunities and discussions with potential partners for the program.
Dec 3, 2025, 4:00 PM
Galectin Therapeutics Reports Q3 2025 Financial Results and Business Update
GALT
Earnings
New Projects/Investments
Guidance Update
- Galectin Therapeutics reported a net loss applicable to common stockholders of $8.2 million, or ($0.13) per share, for the quarter ended September 30, 2025, compared to a net loss of $11.2 million, or ($0.18) per share, for the same period in 2024.
- As of September 30, 2025, the company had $11.5 million in cash and cash equivalents and secured a new $10 million line of credit in July 2025, which is expected to fund operations and R&D through June 30, 2026. Research and development expenses decreased to $2.6 million for Q3 2025, down from $7.6 million in Q3 2024, primarily due to the timing of expenditures related to the NAVIGATE clinical trial which concluded in Q1 2025.
- The company presented new 18-month biomarker analyses from the NAVIGATE trial at the 2025 AASLD Annual Meeting, which further support the antifibrotic and disease-modifying potential of belapectin in patients with compensated MASH cirrhosis and portal hypertension.
- Belapectin demonstrated consistent effects across multiple key biomarkers, including reductions in liver stiffness (LSM), improvements in ELF scores, and reduced PRO-C3 levels, indicating decreased fibrogenesis and a lower risk of hepatic decompensation.
- Galectin Therapeutics has submitted the NAVIGATE data package to the FDA and anticipates feedback on proposed next steps by year-end.
| Metric | Q3 2024 | Q3 2025 |
|---|---|---|
| Research and development expenses ($USD Thousands) | $7,595 | $2,611 |
| General and administrative expenses ($USD Thousands) | $1,471 | $1,587 |
| Net loss applicable to common stockholders ($USD Thousands) | $(11,238) | $(8,223) |
| Basic and diluted net loss per share ($USD) | $(0.18) | $(0.13) |
| Cash and cash equivalents (as of period end) ($USD Thousands) | N/A | $11,525 |
Nov 14, 2025, 12:55 PM
Galectin Therapeutics Presents Promising Clinical Data for Palipectin in MASH Cirrhosis
GALT
New Projects/Investments
- Galectin Therapeutics presented on palipectin, its lead compound, a galectin-3 inhibitor in development for patients with MASH cirrhosis and portal hypertension.
- In the Phase 2B Navigate trial, palipectin at 2 mg significantly reduced the incidence of new varices at 18 months in the per protocol population.
- Palipectin demonstrated a favorable safety profile, with low discontinuation rates due to adverse events and no drug-related serious adverse events reported.
- The company is now focused on advancing discussions with regulatory agencies and identifying a partner to move the program forward.
Oct 21, 2025, 11:00 AM
Galectin Therapeutics Presents Promising Palapectin Data for MASH Cirrhosis at H.C. Wainwright Conference
GALT
- Galectin Therapeutics presented its lead compound, palapectin, a proprietary galectin-3 inhibitor, for patients with MASH cirrhosis and portal hypertension at the H.C. Wainwright Virtual Liver Disease Conference.
- In the NAVIGATE trial, palapectin 2 mg significantly reduced the incidence of new varices at 18 months in the per protocol population of patients with compensated MASH cirrhosis and portal hypertension.
- The 2 mg dose also reduced the incidence of medium or large-sized varices, which are more prone to bleeding.
- Palapectin demonstrated a favorable safety profile, with no drug-related serious adverse events reported in the trial.
- The company is now focused on discussions with regulatory agencies and identifying a partner to advance the program.
Oct 21, 2025, 11:00 AM
Galimedix Therapeutics Completes Phase 1 Study for Oral GAL-101
GALT
New Projects/Investments
- Galimedix Therapeutics has completed its Phase 1 study for orally administered GAL-101, a small molecule designed to target misfolded amyloid beta monomers.
- The study demonstrated that oral GAL-101 was well tolerated and clinically safe, with no serious adverse events, and effectively crosses the blood-brain barrier.
- The pharmacokinetic profile strongly supports advancing GAL-101 into Phase 2 development for Alzheimer’s disease, with a Phase 2 trial planned and fundraising initiated.
- Additionally, Galimedix is conducting a partner-funded Phase 2 clinical trial with GAL-101 eyedrops for dry age-related macular degeneration (dAMD).
Sep 12, 2025, 11:20 AM
Quarterly earnings call transcripts for GALECTIN THERAPEUTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more